Literature DB >> 24035575

Frontotemporal lobar degeneration: diversity of FTLD lesions.

D Seilhean1, F Bielle, I Plu, C Duyckaerts.   

Abstract

Frontotemporal lobar degeneration (FTLD) is a heterogeneous group including both sporadic and familial diseases, characterized by a macroscopic alteration. It may correspond to various cognitive syndromes: behavioral variant of frontotemporal dementia (bvFTD), progressive nonfluent aphasia, and semantic dementia. The neuropathologic classification is now based on identification of the protein that accumulates in neurons and glia: Tau, TAR DNA Binding Protein 43 (TDP-43), and FUsed in Sarcoma (FUS). The disorders in which the corresponding proteins accumulate have been named FTLD-Tau, FTLD-TDP, and FTLD-FUS. FTLD-Tau includes sporadic cases (e.g. Pick's disease) and Tau mutations. FTLD-TDP are subdivided within four types (A, B, C, D) according to the shape and distribution of TDP-43 positive lesions within the associative frontal cortex. The FTLD-FUS group includes atypical FTLD with ubiquitinated lesions (FTLD-U), Neuronal Intermediate Filament Inclusion Disease (NIFID) and Basophilic Inclusion Body Disease (BIBD).
Copyright © 2013. Published by Elsevier Masson SAS.

Entities:  

Keywords:  BIBD; C9ORF72; Dégénérescence lobaire frontotemporale; Démence frontotemporale; FUS; Frontotemporal dementia; Frontotemporal lobar degeneration; Maladie de Pick; Multisystem proteinopathy; NIFID; PCV; Pick's disease; Progranulin; Progranuline; TDP-43; Tau; VCP

Mesh:

Substances:

Year:  2013        PMID: 24035575     DOI: 10.1016/j.neurol.2013.07.015

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  2 in total

1.  Locus Coeruleus Degeneration Differs Between Frontotemporal Lobar Degeneration Subtypes.

Authors:  Nathalie Matti; Keivan Javanshiri; Mattias Haglund; Xavier Saenz-Sardá; Elisabet Englund
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

2.  Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six-month, open-label, self-controlled clinical trial.

Authors:  Pan Li; Wei Quan; Yu-Ying Zhou; Yan Wang; Hui-Hong Zhang; Shuai Liu
Journal:  Exp Ther Med       Date:  2016-04-20       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.